Feb 4, 2015 6:00 am EST NeoGenomics Schedules its Q4 2014 and Full Year 2014 Earnings Release for February 24, 2015
Jan 22, 2015 5:55 pm EST NeoGenomics Raises Revenue Guidance to $25 Million and EPS Guidance to $0.01 - $0.02 per share for Quarter 4, 2014
Dec 16, 2014 7:00 am EST NeoGenomics, the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and the Northwestern Medicine Developmental Therapeutics Institute Launch Collaborative Translational Research Program
Oct 30, 2014 7:00 am EDT NeoGenomics Reports 38% increase in Revenue to a Record $23.2 Million and Adjusted EBITDA of $2.6 Million for the Third Quarter of 2014
Oct 23, 2014 7:00 am EDT NeoGenomics is First to Offer Molecular Testing for Resistance to Bruton Tyrosin Kinase Inhibitors for Chronic Lymphocytic Leukemia
Oct 16, 2014 7:00 am EDT NeoGenomics Launches 315 Gene Next Generation Sequencing Test for Solid Tumor Discovery Profiling
Aug 22, 2014 7:00 am EDT NeoGenomics Announces Closing of Recent Equity Offering and Exercise in Full of Underwriters' Over-Allotment Option
